Paclitaxel Press Release
|01/30/2020 - 08:26||
Oasmia launches the ovarian cancer treatment drug Apealea in Sweden, Denmark and Finland
Oasmia Pharmaceutical AB is launching its product, Apealea® 60 mg, in Sweden, Denmark and Finland. The first batch of the drug has been shipped to distributors in these countries.
|01/28/2020 - 12:11||
Four-year data from ILLUMENATE Pivotal trial reaffirms safety profile of Philips Stellarex low-dose Drug-Coated Balloon
Mortality rates similar to standard of care through four years with excellent rate of follow-up compliance Philips Stellarex is the only low-dose Drug-Coated Balloon (DCB) to demonstrate sustained treatment effect and high safety profile through four years.
|01/27/2020 - 22:01||
AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer
The results were presented during a poster session at the 2020 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium. A copy of the presentation, titled “Phase 1b Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab in Patients with Advanced Pancreatic Cancer” (abstract 693), is available in the Publications & Presentations section of AVEO’s website.
|12/13/2019 - 06:56||
Oral Paclitaxel Yielded Better Outcomes Than Intravenous Paclitaxel for Metastatic Breast Cancer Patients in Phase III Trial
Metastatic breast cancer patients who received an oral formulation of the chemotherapy drug paclitaxel had better response and survival and less neuropathy than patients who received intravenous paclitaxel, according to results of a phase III trial presented at the San Antonio Breast Cancer Symposium, held Dec.
|11/21/2019 - 16:08||
Medtronic Drug-Coated Balloon Receives U.S. FDA Approval to Treat Arteriovenous Fistula Lesions
Clinical Data Demonstrates IN.PACT™ AV DCB Is Safe, Reduces Reinterventions, and Maintains Access for End-Stage Renal Disease Patients Undergoing Dialysis.
|11/05/2019 - 15:25||
Bloomington, Ind. At this years Vascular Interventional Advances (VIVA) conference, Dr. Michael D. Dake presented data on Zilver PTX that supports the devices benefits across different patient groups.
VIVA, held annually in Las Vegas, Nev., is dedicated to advancing vascular procedures and health strategies. At VIVA, Dr. Dake presented the latest data regarding Zilver PTX, Cook Medical’s paclitaxel-coated stent that is used to treat peripheral arterial disease (PAD). His presentation focused on findings that Zilver PTX shows benefits for a variety of patients.
|11/05/2019 - 13:25||
Boston Scientific Announces Positive Data for the Ranger Drug-Coated Balloon and the Eluvia Drug-Eluting Vascular Stent at VIVA19
Late-breaking clinical trial data demonstrate high rates of primary patency and significantly lower rates of clinically-driven target lesion revascularization for peripheral drug-eluting device portfolio.
|11/04/2019 - 07:34||
Halozyme Announces HALO-301 Phase 3 Study Fails To Meet Primary Endpoint
The treatment arm of PEGPH20 in combination with gemcitabine and nab-paclitaxel (ABRAXANE®) failed to demonstrate an improvement in median overall survival compared to gemcitabine and nab-paclitaxel alone (11.2 months compared to 11.5 months, HR=1.00, p=0.9692). While there was a higher response rate in the PEGPH20 treatment arm, this did not translate into an improvement in duration of response, Progression Free Survival or Overall Survival.
|10/31/2019 - 00:19||
DEP gemcitabine outperforms Gemzar in human pancreatic cancer model
Starpharma advances a new internal DEP® candidate, DEP® gemcitabine, into development DEP® gemcitabine demonstrated significantly enhanced anti-tumour activity compared with Gemzar® (gemcitabine), both alone and in combination with Nab‑paclitaxel (Abraxane®), in a human pancreatic cancer model Gemzar® (gemcitabine), used alone or in combination with Abraxane®, is the current standard of care therapy for pancreatic cancer A patent has been filed for Starpharma’s proprietary DEP® gemcitabine, providing coverage to 2040.
|10/15/2019 - 06:00||
Philips introduces new 200mm and 150mm Stellarex 0.035 low-dose drug-coated balloons to broaden treatment options for peripheral artery disease patients
Stellarex’s unique coating enables a low therapeutic drug dose and has demonstrated a significant treatment effect and high safety profile.
|10/14/2019 - 10:03||
Research on cell division provides new clues to how a common cancer treatment works
When chemotherapy was first invented, its premise seemed relatively simple: to curb the growth of tumors by stopping their cells from proliferating. Today, many of these drugs are known to act through different mechanisms, and have turned out to be useful only in certain tumor types and patients.
|10/03/2019 - 18:58||
Immunotherapy for triple negative breast cancer gets initial no for NHS in England
An immunotherapy treatment for triple negative breast cancer has been provisionally rejected for NHS use in England.
|Cancer Research UK|
|10/01/2019 - 14:08||
Third-party evaluation confirms safety profile of Philips Stellarex .035 low-dose drug-coated balloon
Primary safety analysis of Stellarex drug-coated balloon (DCB) three-year data, comprising the largest published, pooled set of randomized controlled trial (RCT) data for a single paclitaxel-based device, shows no difference in mortality between patients treated with the Philips Stellarex DCB and those treated with percutaneous angioplasty, the current standard of care Findings also identified no device-related deaths and no correlation of Stellarex DCB to late all-cause mortality The analyses represent one of industry’s most extensive and rigorous safety assessments of a paclitaxe
|09/28/2019 - 02:10||
BD Announces Publication of an Independent Analysis of Drug-Coated Balloon Safety Data for Femoropopliteal Peripheral Arterial Disease
Independent analysis of LUTONIX® 035 Drug Coated Balloon patient-level data showed no statistically significant mortality increase.
|08/12/2019 - 18:28||
Philips response to updated FDA letter to healthcare providers on paclitaxel devices to treat peripheral artery disease
Amsterdam, The Netherlands - Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced its response to the U.S. Food and Drug Administration’s (FDA) Letter to Health Care Providers regarding treatment of peripheral artery disease (PAD) in the superficial femoropopliteal artery (SFA) with paclitaxel-coated devices.
|08/07/2019 - 12:24||
Medtronic Statement Regarding Updated FDA Letter To Healthcare Providers On Paclitaxel Devices to Treat Peripheral Artery Disease
DUBLIN – August 7, 2019 – Medtronic plc (NYSE:MDT) today issued the following statement regarding the U.S. Food and Drug Administration's (FDA) updated Letter to Healthcare Providers for paclitaxel-devices in patients with peripheral artery disease (PAD) in the superficial femoropopliteal artery (SFA):
|07/29/2019 - 18:20||
UA Researcher Explores New Treatment for Advanced Biliary Tract Cancers
Dr. Rachna Shroff is seeking a “goldmine of information” in her quest to extend survival and improve quality of life for patients with cancers of the liver, gallbladder and pancreas.
|05/28/2019 - 04:06||
Corcept Therapeutics to Present Data from Phase 1/2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Solid Tumors at the American Society of Clinical Oncology Annual Meeting
MENLO PARK, Calif., May 28, 2019 ( ) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, will present data from the Phase 1/2 study of its proprietary, selective cortisol modulator, relacorilant, in combination with nab-paclitaxel (Abraxane®) in patients with solid tumors, at the 2019 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois (May 31 – June 4).
|04/16/2019 - 13:09||
Rexahn and BioSense Global Announce Collaboration and License Agreement for RX-3117 in Greater China
Under the agreement, Rexahn will grant BioSense an exclusive license to develop and commercialize RX-3117 in Greater China. Rexahn will receive an upfront payment and will be eligible to receive additional development, regulatory and commercial milestones up to a total of $226 million contingent on achieving regulatory and commercial goals related to pancreatic cancer and additional indications.
|03/31/2019 - 22:56||
Roches ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase trial
Data from Phase Ib study to be presented at American Association for Cancer Research (AACR) 2019 annual congress 73% overall response rate (ORR) irrespective of PD-L1 status or PI3KCA/AKT1/PTEN alteration status.
|03/28/2019 - 10:37||
The results from Oasmia Pharmaceuticals first study with paclitaxel micellar in humans are published in the scientific journal Advances in Therapy.
The study (OAS-04-01) was a tolerance and pharmacokinetic study where the dose for Apealea (paclitaxel micellar) was determined. This phase I study was conducted at two clinics in Sweden located in Lund and Umeå between 2004 and 2007. The 34 patients included in the study had different forms of refractory cancers with solid tumours.
|03/25/2019 - 12:27||
Oasmia Pharmaceutical AB receives positive opinion from the European Medicines Agency to add efficacy data to the approved Apealea product information
Uppsala, Sweden, March 25, 2019 – Oasmia Pharmaceutical AB (NASDAQ: OASM) today announce that the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a type II variation application to add efficacy data to the Apealea product information.
|03/21/2019 - 16:28||
BD Statement on Paclitaxel-Coated Devices
FRANKLIN LAKES, N.J. (March 21, 2019) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement related to the recent letter from FDA to health care providers regarding paclitaxel-coated devices:
|03/08/2019 - 10:36||
FDA Grants Genentechs Tecentriq in Combination With Abraxane Accelerated Approval for People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). The FDA’s Accelerated Approval Program allows conditional approval of a medicine that fills an unmet medical need for a serious or life-threatening disease or condition.
|03/03/2019 - 21:40||
Rexahn Announces Target Enrollment Reached in Phase 2a Clinical Trial of RX-3117 in Combination With ABRAXANE in First-line Metastatic Pancreatic Cancer Patients
This multicenter, single-arm, open-label study is designed to evaluate the safety and efficacy of RX-3117 in combination with ABRAXANE in first-line metastatic pancreatic cancer patients. As of February 27, 2019, the target enrollment of 40 patients has been achieved. Patients were enrolled into the study from 10 centers in the US. The primary endpoint is progression free survival and study is expected to be completed in the second half of 2019.